EGFR and non-small cell lung carcinoma: Importantly, Fra-2 is also involved in the mechanisms of drug response; in particular, Fra-2 overexpression has been demonstrated in NSCLC cells and patients’ tissues with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib [62].